^
BIOMARKER:

FGFR3 expression

i
Other names: FGFR3, ACH, CD333, CEK2, JTK4, Fibroblast growth factor receptor 3
Entrez ID:
12d
Targetable mutations were mainly detected in BLCA, and S249C, Y373C, G370C, and R248C were hotspot mutations that could be targeted by an FDA approved erdafitinib...FGFG3 abnormal expression and alterations exhibited clinical correlations with patient prognosis in several tumors. This work exhibited the full alteration spectrum of FGFR3 and indicated several new clues for their application as potential therapeutic targets and prognostic indicators.
Clinical • Journal • Pan tumor
|
FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3)
|
FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 R248C • FGFR3 expression • FGFR3 G370C
|
Balversa (erdafitinib)
1m
Assessment of FGFR mRNA expression identified a high-risk subgroup of patients with mUCa. These patients showing overexpression of FGFR3 mRNA were found to have unfavorable DSS after CPI treatment. Using this approach may be suitable for identifying a patient population with poor response to CPI treatment, which may benefit from early FGFR inhibition.
Journal • Checkpoint inhibition
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR2 fusion • FGFR3 mutation • FGFR3 overexpression • FGFR3 fusion • FGFR1 expression • FGFR2b expression • FGFR3 expression • FGF3 overexpression • FGFR2 expression
2ms
Conclusion A 24-gene bladder cancer specific hypoxia signature is sensitive to changing oxygen levels in vitro . Increasing signatures scores in response to hypoxia is more consistent than the variable responses seen in the expression of genes associated with bladder cancer subtypes.
Preclinical
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • CA9 (Carbonic anhydrase 9)
|
HER-2 expression • EGFR expression • FGFR3 expression • CA9 expression
2ms
Conclusion A 24-gene bladder cancer specific hypoxia signature is sensitive to changing oxygen levels in vitro . Increasing signatures scores in response to hypoxia is more consistent than the variable responses seen in the expression of genes associated with bladder cancer subtypes.
Preclinical
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • CA9 (Carbonic anhydrase 9)
|
HER-2 expression • EGFR expression • FGFR3 expression • CA9 expression
2ms
Conclusion A 24-gene bladder cancer specific hypoxia signature is sensitive to changing oxygen levels in vitro . Increasing signatures scores in response to hypoxia is more consistent than the variable responses seen in the expression of genes associated with bladder cancer subtypes.
Preclinical
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • CA9 (Carbonic anhydrase 9)
|
HER-2 expression • EGFR expression • FGFR3 expression • CA9 expression
2ms
Conclusion A 24-gene bladder cancer specific hypoxia signature is sensitive to changing oxygen levels in vitro . Increasing signatures scores in response to hypoxia is more consistent than the variable responses seen in the expression of genes associated with bladder cancer subtypes.
Preclinical
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • CA9 (Carbonic anhydrase 9)
|
HER-2 expression • EGFR expression • FGFR3 expression • CA9 expression
3ms
We propose that t(4;14) MM is a genomically and immunologically heterogeneous disease. Single cell analysis of larger cohorts is required to build on our findings.
IO biomarker
|
FGFR3 (Fibroblast growth factor receptor 3) • CRBN (Cereblon) • CD14 • SDC1 (Syndecan 1) • CTAG2 (Cancer/testis antigen 2)
|
Chr t(4;14) • FGFR3 expression • SDC1 positive
3ms
In conclusion, our data point on the identification of molecular markers predictive for AK rapid progression through the "differentiated" pathway. Our results also represent an important step that, in future, will help to clarify the molecular mechanisms underlying FGFR signaling deregulation in epithelial tissues during the switch from the pre-neoplastic to the oncogenic malignant phenotype.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • FGF2 (Fibroblast Growth Factor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
FGFR3 expression
3ms
In early bladder cancer FGFR3 alterations are tightly associated with a characteristic FGFR mRNA signature . Mutation/Fusion of FGFR3 results in high FGFR3 but low FGFR1 and FGFR4 mRNA expression, which might be i.a . relevant for the response to FGFR inhibition and important to predict outcome of FGFR inhibitors .
Clinical • Real-world evidence
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4) • KRT5 (Keratin 5) • KRT20 (Keratin 20)
|
FGFR3 mutation • FGFR3 fusion • FGFR1 expression • FGFR1 fusion • FGFR3 expression • FGFR4 expression
3ms
First-line treatment with the RP2D of R+A achieved favorable clinical efficacy and tolerability in pts with cisplatin-ineligible, metastatic UC characterized by high FGFR1/3 mRNA expression and generally low/negative PD-L1 expression . Encouraging efficacy was observed regardless of PD-L1 expression or FGFR3 mutation status, warranting future investigation.
Combination therapy • P1/2 data • Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
PD-L1 expression • PD-L1 overexpression • FGFR3 mutation • PD-L1 negative • FGFR3 overexpression • FGFR1 expression • FGFR fusion • FGFR3 expression • FGF3 overexpression
|
cisplatin • Tecentriq (atezolizumab) • rogaratinib (BAY1163877)
5ms
In conclusion, our study demonstrated that UTUC patients who develop MIBC recurrence after RNU exhibit the clinical characteristics of subsequent IVR more than those of primary UTUC. Of note, MIBC subsequent to UTUC may have favorable outcomes, probably due to the different molecular biological background compared from primary MIBC.
Clinical • Journal
|
TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3)
|
TP53 expression • FGFR3 expression
5ms
This significant observation can be therapeutically utilized towards developing new effective treatments for KRAS mutant CRC patients. Further analysis is currently in progress to verify the proposed molecular mechanism outlining how eIF4E and FGFR3 interact with PRMT5 and KRAS in CRC.
KRAS (KRAS proto-oncogene GTPase) • FGFR3 (Fibroblast growth factor receptor 3) • PRMT5 (Protein Arginine Methyltransferase 5)
|
KRAS mutation • FGFR3 overexpression • FGFR3 expression • FGF3 overexpression
5ms
Our results suggest that high FGFR3 expression is associated with p16 negative status and mp53 expression in OPSCC and correlates with a worse clinical outcome. The biological relationship between FGFR3 and mp53 in OPSCC deserves further investigation.
Journal
|
TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor)
|
TP53 mutation • FGFR3 mutation • TP53 expression • CDKN2A negative • FGFR3 expression
7ms
The FGF2-FGFR3 axis may be a new direction of targeted therapy for esophageal squamous cell carcinoma. FGF2 and FGFR3 may be used as prognostic markers of esophageal squamous cell carcinoma.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • FGF2 (Fibroblast Growth Factor 2)
|
FGFR3 expression
8ms
tumor grade in association with PD-L1 and FGFR3 expression can be considered as a complex predictor for primary luminal NMIBC progression.
Journal • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3)
|
PD-L1 expression • PD-L1 overexpression • FGFR3 mutation • FGFR3 expression
9ms
Circ_0061825 was characterized using ribonuclease (RNase) R digestion, actinomycin D and subcellular fractionation assays...Moreover, miR-593-3p overexpression hindered BC cell malignant progression in vitro by down-regulating FGFR3. Our current work provided evidence that circ_0061825, an up-regulated circRNA in BC, regulated BC malignant progression at least in part through targeting the miR-593-3p/FGFR3 axis, illuminating a novel therapeutic target for BC management.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 expression
|
dactinomycin
11ms
These results indicate that targeting FGFR3 may represent a therapeutic option for TNBC, but only for patients with oncogenic FGFR3 alterations, such as the FGFR3-TACC3 fusion. Video abstract.
Journal • PARP Biomarker
|
FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3) • FRS2 (Fibroblast Growth Factor Receptor Substrate 2)
|
FGFR3 mutation • FGFR3 fusion • FGFR3 expression
11ms
Clinical • Phase classification
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 expression
|
Truseltiq (infigratinib)
1year
The overexpression of the EGFR and PIK3CA was not found to be related to tested mutations and so far these two molecules are not convenient for bladder cancer targeted therapy. On the other hand the overexpression of FGFR3 and CDKN2A could be due to detected mutations.
EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin-dependent kinase inhibitor 2A)
|
PIK3CA mutation • EGFR overexpression • FGFR3 mutation • CDKN2A mutation • FGFR3 S249C • FGFR3 overexpression • FGFR3 Y375C • FGFR3 expression • PIK3CA overexpression
1year
PATIENT SUMMARY: We identified and characterized expression subtypes of high-grade stage T1 bladder cancer that are biologically heterogeneous and have variable responses to bacillus Calmette-Guérin treatment. We validated the subtypes and describe a single-patient classifier.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • E2F1 (E2F transcription factor 1)
|
MYC expression • FGFR3 expression
1year
Clinical • P2 data • Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • FGF (Fibroblast Growth Factor)
|
HER-2 overexpression • FGFR3 overexpression • FGFR3 expression
|
Herceptin (trastuzumab) • Pemazyre (pemigatinib) • dexloxiglumide (CR2017)
1year
In this report, we found that these FGFR3 mutations were associated with favorable features and prognosis of bladder cancer compared with patients with FGFR3 overexpressed tumors only. As a consequence, patients with FGFR3 mutant tumors would be more likely to benefit from anti-FGFR3 therapy than patients with FGFR3 protein overexpression only.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
TP53 mutation • FGFR3 mutation • FGFR3 overexpression • FGFR3 expression
1year
Mechanistically, circFGFR3 upregulates E2F1 expression by sponging miR-29a-3p, and the overexpression of E2F1 or the suppression of miR-29a-3p induces OC cell EMT. Therefore, circFGFR3 serves as a promoter of OC by inducing OC cell EMT via the miR-29a-3p/E2F1 axis and circFGFR3 may be a prognostic biomarker for OC patients.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • E2F1 (E2F transcription factor 1)
|
FGFR3 expression
1year
We did not find any robust association, mainly when analyzing the landscape of alterations defining tumors with higher biological FGFR activity. Overall, FGFR3 activity and gene alterations did not provide sufficiently robust data to exclude patients whose tumors harbor these alterations from neoadjuvant immunotherapy trials.
Clinical • Journal • PD(L)-1 Biomarker
|
FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR3 mutation • FGFR3 fusion • FGFR3 expression
|
Keytruda (pembrolizumab)
1year
The assessment of FGFR mRNA by standardized RT-qPCR identified a high risk UCB patient cohort, which does have inferior disease specific survival despite IO treatment and does overexpress FGFR3 mRNA. The assessment of FGFR mRNA levels by using this standardized, locally applicable FGFR testing could identify an FGFR inhibitor target population with poor response to IO treatment which is twice the size as currently detected by FGFR genomic alterations alone. Source of Funding: Janssen, Research & Development, LLC, USA
Clinical • PD(L)-1 Biomarker • IO biomarker
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor)
|
PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion • FGFR3 expression • FGFR expression
1year
Interestingly, different activities were observed in antibody-induced receptor degradation indicating that APLP2 and CD63 regulate FGFR3 trafficking via distinct mechanisms. FGFR3xAPLP2 AF bispecifics enhanced receptor degradation compared to parental FGFR3 antibody, while FGFR3xCD63 AF bispecifics increased growth inhibition without receptor degradation.Our proof-of-concept case study suggests that AF bispecific antibodies can be used as a single novel modality to offer more potent inhibition against diverse mechanisms of oncogenic receptor activation.
HER-2 (Human epidermal growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3)
|
FGFR3 mutation • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 R248C • FGFR3 expression • FGFR3 G370C
1year
FGF9 acts via FGFR3-IIIb/IIIc to enhance growth and aggressiveness of HCC cells. Accordingly, blockade of the FGF9-FGFR3-IIIb/IIIc axis may be an efficient therapeutic option for HCC patients.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGF (Fibroblast Growth Factor)
|
FGFR3 expression
|
Truseltiq (infigratinib)
over1year
The assessment of FGFR mRNA by standardized RT-qPCR identified a high risk UCB patient cohort, which does have inferior disease specific survival despite IO treatment and does over express FGFR3 mRNA. The assessment of FGFR mRNA levels by using this standardized, locally applicable FGFR testing could identify an FGFR inhibitor target population with poor response to IO treatment which is twice the size as currently detected by FGFR genomic alterations alone.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor)
|
PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 overexpression • FGFR3 fusion • FGFR3 expression • FGFR expression
over1year
This data suggests that while FGFR1-3 genes are overall expressed in CRC and lung, some cases may have significantly high expression of FGFR1-3 and perhaps these cases should be singled out for treatment with FGFR inhibitors. Furthermore, NGS testing for mutations significantly more efficient and can detect significant number of mutations that can be missed if PCR-based testing is used. NGS testing of DNA and RNA is the most appropriate testing for abnormalities in FGFR1-4.
Next-generation sequencing
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • FGF (Fibroblast Growth Factor)
|
FGFR1 amplification • FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion • FGFR1 expression • FGFR1 fusion • FGFR3 expression • FGFR expression • FGFR4 expression